Haoxi Health CEO Buys 40 Million Shares at $0.02 Amid Reverse Split—A Bold Gamble or Confidence Signal?

Insider Buying in a Low‑Price Stock: A Signal of Confidence or a Risky Gambit? On May 19, 2026, Haoxi Health Technology Ltd. saw its chief executive, Fan Zhen, purchase 40 million Class B shares at $0.02 each—about 1.4 % above the closing price of $0.014. With a market cap of just $1.34 million and a 52‑week low of $0.0131, the transaction occurred in the midst of a steep 59 % weekly decline and an almost 99 % yearly loss. The buy, disclosed in a Form 4 filing, came just two days after a reverse split announcement that would raise the nominal value of each share to $0.32.

What Does a Large Buy Mean When the Share Is Near Zero? For a company trading at pennies, a sizable insider purchase is unusual. Typically, such moves signal either a belief that the stock is undervalued or a strategic shift that may influence governance. Here, the $0.02 purchase price, slightly above the market, suggests a willingness to pay a premium for control—indeed, the acquisition gives Fan Zhen a majority of voting power in Class B shares. Investors should note that the purchase coincided with a reverse split, a classic mechanism to boost liquidity and attract institutional buyers. The timing also aligns with a positive sentiment score (+45) and high buzz (65 %) on social media, indicating that the market may be interpreting the move as a bullish sign.

Implications for Investors and the Company’s Future If the reverse split and the insider buy succeed in elevating the share price, Haoxi could move from a fringe penny stock to a more tradable security, potentially widening its investor base. However, the company’s fundamentals remain fragile: a 98 % annual decline and a valuation of only $1.34 million suggest significant upside risk. The proceeds from the sale are earmarked for working capital—critical for a company in a competitive online marketing niche—yet the lack of disclosed long‑term growth strategy leaves investors uncertain about how the capital will be deployed to reverse the current downward trajectory.

A Profile of Fan Zhen: The Risk‑Tolerant CEO Fan Zhen’s transaction history is sparse but telling. In April 2026, a Form 3 filing indicated a holding of 690,800 Class B shares, reflecting an early stake in the company. The recent 40 million‑share purchase marks a dramatic escalation—an 80‑fold increase in stake that signals strong personal conviction. As CEO and Chairman, Fan Zhen’s moves suggest a willingness to inject capital personally, potentially to steer the company through a critical restructuring phase. His actions mirror those of CEOs who use insider transactions to demonstrate confidence, yet they also expose him to heightened scrutiny if the market does not respond favorably.

Conclusion: Confidence with Caveats For investors, Fan Zhen’s substantial buy coupled with the reverse split offers a nuanced narrative: it could be a genuine confidence boost that propels the stock to a more sustainable price, or it could be a speculative gamble in a company struggling to find footing. The key will be whether the combined effect of a higher nominal price and increased insider ownership translates into improved liquidity, stronger governance, and ultimately a reversal of Haoxi’s steep decline. As always, due diligence into the company’s strategic plans and cash flow projections will be essential before committing capital to a penny‑priced play.